Cargando…

Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?

SIMPLE SUMMARY: Immune checkpoint blockade (ICB) has emerged as a very promising therapeutic option for patients, demonstrating unprecedented, durable responses in several difficult-to-treat cancers. Despite research indicating a strong potential for ICB in uterine leiomyosarcomas (uLMSs), a clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: De Wispelaere, Wout, Annibali, Daniela, Tuyaerts, Sandra, Lambrechts, Diether, Amant, Frédéric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122870/
https://www.ncbi.nlm.nih.gov/pubmed/33922556
http://dx.doi.org/10.3390/cancers13092040
_version_ 1783692740142301184
author De Wispelaere, Wout
Annibali, Daniela
Tuyaerts, Sandra
Lambrechts, Diether
Amant, Frédéric
author_facet De Wispelaere, Wout
Annibali, Daniela
Tuyaerts, Sandra
Lambrechts, Diether
Amant, Frédéric
author_sort De Wispelaere, Wout
collection PubMed
description SIMPLE SUMMARY: Immune checkpoint blockade (ICB) has emerged as a very promising therapeutic option for patients, demonstrating unprecedented, durable responses in several difficult-to-treat cancers. Despite research indicating a strong potential for ICB in uterine leiomyosarcomas (uLMSs), a clinical trial assessing response to ICB monotherapy in uLMSs showed no clinical benefit. Resistance to ICB has been studied extensively in a variety of tumor types, but the resistance mechanisms explaining the lack of response to ICB in uLMSs remain largely unexplored. By elucidating and targeting mechanisms of resistance, treatments can be tailored to improve the effectiveness of ICB and accelerate its clinical implementation. Therefore, in this review we will explore what is known about the immunosuppressive microenvironment of uLMSs, link these data to possible resistance mechanisms extrapolated from other cancer types, and discuss potential therapeutic strategies to overcome resistance. ABSTRACT: The onset of immune checkpoint blockade (ICB) therapy over the last decade has transformed the therapeutic landscape in oncology. ICB has shown unprecedented clinical activity and durable responses in a variety of difficult-to-treat cancers. However, despite these promising long-term responses, a majority of patients fail to respond to single-agent therapy, demonstrating primary or acquired resistance. Uterine leiomyosarcoma (uLMS) is a rare high-risk gynecological cancer with very limited treatment options. Despite research indicating a strong potential for ICB in uLMS, a clinical trial assessing the response to immunotherapy with single-agent nivolumab in advanced-stage uLMS showed no clinical benefit. Many mechanisms of resistance to ICB have been characterized in a variety of tumor types, and many more continue to be uncovered. However, the mechanisms of resistance to ICB in uLMS remain largely unexplored. By elucidating and targeting mechanisms of resistance, treatments can be tailored to improve clinical outcomes. Therefore, in this review we will explore what is known about the immunosuppressive microenvironment of uLMS, link these data to possible resistance mechanisms extrapolated from other cancer types, and discuss potential therapeutic strategies to overcome resistance.
format Online
Article
Text
id pubmed-8122870
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81228702021-05-16 Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types? De Wispelaere, Wout Annibali, Daniela Tuyaerts, Sandra Lambrechts, Diether Amant, Frédéric Cancers (Basel) Review SIMPLE SUMMARY: Immune checkpoint blockade (ICB) has emerged as a very promising therapeutic option for patients, demonstrating unprecedented, durable responses in several difficult-to-treat cancers. Despite research indicating a strong potential for ICB in uterine leiomyosarcomas (uLMSs), a clinical trial assessing response to ICB monotherapy in uLMSs showed no clinical benefit. Resistance to ICB has been studied extensively in a variety of tumor types, but the resistance mechanisms explaining the lack of response to ICB in uLMSs remain largely unexplored. By elucidating and targeting mechanisms of resistance, treatments can be tailored to improve the effectiveness of ICB and accelerate its clinical implementation. Therefore, in this review we will explore what is known about the immunosuppressive microenvironment of uLMSs, link these data to possible resistance mechanisms extrapolated from other cancer types, and discuss potential therapeutic strategies to overcome resistance. ABSTRACT: The onset of immune checkpoint blockade (ICB) therapy over the last decade has transformed the therapeutic landscape in oncology. ICB has shown unprecedented clinical activity and durable responses in a variety of difficult-to-treat cancers. However, despite these promising long-term responses, a majority of patients fail to respond to single-agent therapy, demonstrating primary or acquired resistance. Uterine leiomyosarcoma (uLMS) is a rare high-risk gynecological cancer with very limited treatment options. Despite research indicating a strong potential for ICB in uLMS, a clinical trial assessing the response to immunotherapy with single-agent nivolumab in advanced-stage uLMS showed no clinical benefit. Many mechanisms of resistance to ICB have been characterized in a variety of tumor types, and many more continue to be uncovered. However, the mechanisms of resistance to ICB in uLMS remain largely unexplored. By elucidating and targeting mechanisms of resistance, treatments can be tailored to improve clinical outcomes. Therefore, in this review we will explore what is known about the immunosuppressive microenvironment of uLMS, link these data to possible resistance mechanisms extrapolated from other cancer types, and discuss potential therapeutic strategies to overcome resistance. MDPI 2021-04-23 /pmc/articles/PMC8122870/ /pubmed/33922556 http://dx.doi.org/10.3390/cancers13092040 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
De Wispelaere, Wout
Annibali, Daniela
Tuyaerts, Sandra
Lambrechts, Diether
Amant, Frédéric
Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?
title Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?
title_full Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?
title_fullStr Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?
title_full_unstemmed Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?
title_short Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?
title_sort resistance to immune checkpoint blockade in uterine leiomyosarcoma: what can we learn from other cancer types?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122870/
https://www.ncbi.nlm.nih.gov/pubmed/33922556
http://dx.doi.org/10.3390/cancers13092040
work_keys_str_mv AT dewispelaerewout resistancetoimmunecheckpointblockadeinuterineleiomyosarcomawhatcanwelearnfromothercancertypes
AT annibalidaniela resistancetoimmunecheckpointblockadeinuterineleiomyosarcomawhatcanwelearnfromothercancertypes
AT tuyaertssandra resistancetoimmunecheckpointblockadeinuterineleiomyosarcomawhatcanwelearnfromothercancertypes
AT lambrechtsdiether resistancetoimmunecheckpointblockadeinuterineleiomyosarcomawhatcanwelearnfromothercancertypes
AT amantfrederic resistancetoimmunecheckpointblockadeinuterineleiomyosarcomawhatcanwelearnfromothercancertypes